PriceTargets.com logo

YS Biopharma - YS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.25
  • Forecasted Upside: 556.25%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.80 As of 04/26/2024 01:00 AM ET
▲ +0.01 (1.27%)

This chart shows the closing price for YS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New YS Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YS

Analyst Price Target is $5.25
▲ +556.25% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for YS Biopharma in the last 3 months. The average price target is $5.25, with a high forecast of $5.25 and a low forecast of $5.25. The average price target represents a 556.25% upside from the last price of $0.80.

This chart shows the closing price for YS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in YS Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023Noble FinancialInitiated CoverageOutperform$5.25Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

YS Biopharma logo
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Read More

Today's Range

Now: $0.80
Low: $0.77
High: $0.85

50 Day Range

MA: $0.68
Low: $0.38
High: $0.94

52 Week Range

Now: $0.80
Low: $0.35
High: $1.97

Volume

39,764 shs

Average Volume

170,173 shs

Market Capitalization

$74.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of YS Biopharma?

The following Wall Street research analysts have issued stock ratings on YS Biopharma in the last twelve months: Noble Financial.
View the latest analyst ratings for YS.

What is the current price target for YS Biopharma?

1 Wall Street analysts have set twelve-month price targets for YS Biopharma in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 556.3%. Noble Financial has the highest price target set, predicting YS will reach $5.25 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $5.25 for YS Biopharma in the next year.
View the latest price targets for YS.

What is the current consensus analyst rating for YS Biopharma?

YS Biopharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YS will outperform the market and that investors should add to their positions of YS Biopharma.
View the latest ratings for YS.

What other companies compete with YS Biopharma?

Other companies that are similar to YS Biopharma include Affimed, Connect Biopharma, Assertio, Assembly Biosciences and Corvus Pharmaceuticals. Learn More about companies similar to YS Biopharma.

How do I contact YS Biopharma's investor relations team?

YS Biopharma's physical mailing address is Unit 1101 11th Floor 1 Lyndhurst Tower 1 Lyndhurst Terrace, Central K3, . The company's listed phone number is 852-2155-7212 and its investor relations email address is [email protected]. The official website for YS Biopharma is www.ysbiopharm.com. Learn More about contacing YS Biopharma investor relations.